BioMarin Pharmaceutical Inc.
BMRN
$58.14
$0.290.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.84% | 15.65% | 28.28% | 19.61% | 8.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.84% | 15.65% | 28.28% | 19.61% | 8.79% |
| Cost of Revenue | -6.02% | -1.30% | 47.18% | 2.03% | 7.43% |
| Gross Profit | 36.46% | 20.24% | 22.94% | 38.46% | 10.23% |
| SG&A Expenses | -8.76% | -34.19% | 17.48% | 8.69% | 7.05% |
| Depreciation & Amortization | -66.10% | -36.66% | -68.06% | -8.48% | -8.76% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.61% | -20.82% | 14.71% | 4.31% | 6.81% |
| Operating Income | 185.35% | 842.98% | 273.11% | 143.23% | 25.73% |
| Income Before Tax | 125.58% | 777.73% | 222.64% | 86.61% | 85.96% |
| Income Tax Expenses | 210.35% | 4,364.89% | 2,096.82% | 69.00% | 185.94% |
| Earnings from Continuing Operations | 109.43% | 513.22% | 162.72% | 91.25% | 74.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 109.43% | 513.22% | 162.72% | 91.25% | 74.35% |
| EBIT | 185.35% | 842.98% | 273.11% | 143.23% | 25.73% |
| EBITDA | 132.45% | 418.73% | 136.43% | 104.37% | 19.12% |
| EPS Basic | 107.14% | 506.11% | 159.72% | 89.03% | 72.32% |
| Normalized Basic EPS | 146.43% | 1,257.41% | 218.79% | 138.94% | 36.06% |
| EPS Diluted | 108.02% | 644.69% | 160.67% | 87.65% | 72.16% |
| Normalized Diluted EPS | 152.72% | 1,239.68% | 212.92% | 135.02% | 34.27% |
| Average Basic Shares Outstanding | 1.11% | 1.17% | 1.17% | 1.15% | 1.18% |
| Average Diluted Shares Outstanding | -1.40% | 2.47% | 3.12% | 2.82% | 2.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |